News & Events about Acumen Pharmaceuticals Inc.
TipRanks Financial Blog
1 year ago
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals (ABOS Research Report), with a price t... In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals (ABOS –...
Acumen Pharmaceuticals (NASDAQ:ABOS Get Rating) and Elevation Oncology (NASDAQ:ELEV Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, ...
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing a novel ...
HC Wainwright restated their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS Get Rating) in a report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. ABOS has been the subject of a number of other research reports. ...
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease (AD), today announced Derrell ...